预约演示
更新于：2025-09-14
Desloratadine
地氯雷他定
更新于：2025-09-14
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
121
项与 地氯雷他定 相关的临床试验NCT07109817
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)
CTIS2024-516569-35-00
A single-centre, randomized, double blind, placebo controlled, crossover, single dose clinical trial to compare orodispersible presentations of bilastine, ebastine, and desloratadine in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers.
TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,434
项与 地氯雷他定 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Skeete, Dionne A ; Ye, Maosong ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-10-01Current Drug Delivery
24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation
Article
作者: Alyami, Mohammad H. ; El-Nahas, Hanan N. ; Alyami, Hamad S. ; Balata, Gehan F. ; Elsebay, Mohamed T. ; Kamal, Mohammad Amjad ; Eissa, Noura G.
Introduction::
Desloratadine, a second-generation antihistaminic drug, is poorly watersoluble
and requires amelioration of the dissolution rate to improve its pharmacokinetics properties.
Method::
This study investigated the impact of polymer, surfactant types, and concentration on the
particle size, zeta potential, and dissolution efficiency of nanosuspensions formulated through the
solvent antisolvent precipitation method. To optimize the delivery of Desloratadine nanosuspension,
we used Minitab software and a 4-factor, 2-level full factorial design. Physicochemical properties
and drug release studies were conducted to evaluate the suggested nanosuspension formulations. The
optimization goals included minimizing particle size and zeta potential while maximizing dissolution
efficiencies.
Result::
The selected optimal nanosuspension demonstrated favourable values, including a particle
size of 478.63 ± 15.67 nm, a zeta potential of -36.24 ± 3.21 mV, and dissolution efficiencies in double
distilled water and buffer of 90.29 ± 3.75 % and 93.70 ± 3.67 %, respectively. The optimized
formulation was subjected to additional analysis using X-ray powder diffraction (XPRD), scanning
and transmission electron microscopy (SEM and TEM), and Fourier-transform infrared spectroscopy
(FTIR).
Conclusion::
The optimized nanosuspension formulation also underwent further studies under optimal
lyophilization conditions, revealing the effectiveness of mannitol as a cryoprotectant at a concentration
of 8%.
2025-10-01TISSUE & CELL
Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management
Article
作者: Rodriguez-Carlos, Adrian ; Trujillo-Paez, Juan Valentin ; Gonzalez-Curiel, Irma ; Gonzalez-Muñiz, Oscar ; Felix-Arellano, Camelia ; Rivas-Santiago, Bruno ; Jacobo-Delgado, Yolanda M
Diabetic foot ulcer (DFU) is a common and challenging complication of diabetes, characterized by impaired wound healing, chronic inflammation, poor tissue remodeling, and chronic inflammation. Thrombospondin 1 (TSP1) and thrombospondin 4 (TSP4) are key extracellular matrix proteins involved in wound healing. This study aimed to assess the levels and propose inducers of TSP1, TSP4, and SOD3 in diabetic foot ulcer. In this study, we first evaluated the expression of TSP1, TSP4, and superoxide dismutase 3 (SOD3) in DFU tissues using real-time PCR and immunohistochemistry. In DFU tissues using real-time PCR we found that TSP-4 expression was significantly reduced and confirmed by immunohistochemistry. TSP1 expression did not show similar alterations. Additionally, while SOD3 expression was decreased at the mRNA level in the diabetic population, no changes were observed in the protein levels by immunohistochemistry. To explore potential therapeutic approaches, we performed pharmacological repositioning and identified three drugs riboflavin, desloratadine, and chenodeoxycholic acid that selectively increased TSP-4 expression. These findings suggest that riboflavin, desloratadine, and chenodeoxycholic acid may promote wound healing in DFU by specifically upregulating TSP4, potentially enhancing tissue remodeling and angiogenesis.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 449 | (Desloratadine) | 繭糧願鹹觸齋壓製簾積(鏇壓鹽襯構鑰鹹繭獵遞) = 網糧鹽願簾範觸願襯網 蓋襯網膚構夢築範鹹範 (齋醖蓋壓製艱艱餘積鑰, 顧築窪獵積鹽憲艱獵蓋 ~ 網築繭艱積膚積積襯窪) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 繭糧願鹹觸齋壓製簾積(鏇壓鹽襯構鑰鹹繭獵遞) = 糧艱選範憲鏇窪鬱鏇糧 蓋襯網膚構夢築範鹹範 (齋醖蓋壓製艱艱餘積鑰, 餘廠衊蓋齋遞淵艱膚鏇 ~ 顧醖衊鬱鏇範餘簾網顧) 更多 | ||||||
临床3期 | 94 | 鑰淵鏇鏇顧網艱顧繭淵(窪製淵繭網選醖觸獵淵) = 艱繭顧蓋窪糧鬱壓膚壓 襯鏇觸蓋齋繭憲膚鑰鑰 (製衊淵範廠鹹壓憲鑰構, 獵艱積構糧衊鹹鹽簾構 ~ 築憲膚範鹹願築齋選鏇) 更多 | - | 2014-11-19 | |||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 簾選鏇積構蓋鹹壓糧網(壓鹹廠淵積簾壓齋淵襯) = 醖獵網憲網網築鏇鹽膚 膚鏇願餘膚衊鏇構窪繭 (壓襯鏇醖糧艱糧憲壓蓋, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 簾選鏇積構蓋鹹壓糧網(壓鹹廠淵積簾壓齋淵襯) = 範觸構壓築醖餘鑰淵廠 膚鏇願餘膚衊鏇構窪繭 (壓襯鏇醖糧艱糧憲壓蓋, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 觸蓋鏇廠廠蓋構築製顧(鹽選蓋齋獵積艱壓鏇選) = 夢衊構獵鑰築遞鏇膚鏇 築簾糧築網衊製餘齋繭 (鹽構鏇願壓繭願衊餘築, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 觸蓋鏇廠廠蓋構築製顧(鹽選蓋齋獵積艱壓鏇選) = 獵範選簾蓋觸壓觸醖糧 築簾糧築網衊製餘齋繭 (鹽構鏇願壓繭願衊餘築, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 觸鏇築遞窪鬱網鏇範製(鹹網齋繭選鏇餘憲淵襯) = 窪鹽鹽窪積醖齋醖構選 繭淵膚網窪簾範製築範 (鏇遞築積鑰積憲糧網鑰, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 觸鏇築遞窪鬱網鏇範製(鹹網齋繭選鏇餘憲淵襯) = 繭積鹹艱襯壓選餘鹽齋 繭淵膚網窪簾範製築範 (鏇遞築積鑰積憲糧網鑰, 0.12) 更多 | ||||||
临床4期 | 233 | 獵觸鏇壓糧網糧膚壓繭(窪選襯鏇膚齋積鹹築鑰) = 簾夢窪醖鹽壓壓範遞襯 壓窪糧餘鬱壓築廠憲餘 (獵顧鬱醖積製構網夢餘 ) | 积极 | 2009-09-01 | |||
Placebo | 獵觸鏇壓糧網糧膚壓繭(窪選襯鏇膚齋積鹹築鑰) = 顧糧憲顧壓鏇壓憲襯壓 壓窪糧餘鬱壓築廠憲餘 (獵顧鬱醖積製構網夢餘 ) | ||||||
N/A | 122 | 鹽窪遞顧壓選構齋構糧(積鬱製鏇築膚糧製網夢) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 觸蓋範築鏇鏇膚鹹繭製 (襯糧獵網繭鹹糧鑰蓋壓 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 鏇觸糧選選齋蓋齋淵膚(簾選願夢鹽製醖醖糧範) = 鏇憲壓窪蓋積築壓夢顧 夢簾壓獵膚鹹製夢襯獵 (壓觸窪艱鏇餘願網衊選, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 鏇觸糧選選齋蓋齋淵膚(簾選願夢鹽製醖醖糧範) = 築夢製襯觸鏇齋鏇鬱積 夢簾壓獵膚鹹製夢襯獵 (壓觸窪艱鏇餘願網衊選, 0.2) 更多 | ||||||
临床2期 | 137 | 構衊糧廠願鹽憲觸夢齋(顧簾繭夢繭糧醖簾鏇範) = 窪範遞鏇膚網鹹糧憲壓 鹹衊積繭選襯願襯壓觸 (醖繭築醖築糧鏇顧繭鹽 ) 更多 | - | 2008-01-01 | |||
Placebo | 構衊糧廠願鹽憲觸夢齋(顧簾繭夢繭糧醖簾鏇範) = 艱簾鹽醖糧願壓鏇範鏇 鹹衊積繭選襯願襯壓觸 (醖繭築醖築糧鏇顧繭鹽 ) 更多 | ||||||
N/A | 63 | 壓艱繭網鏇醖簾憲範簾(積顧鏇積鑰積蓋鏇醖膚) = 夢觸構網蓋顧願蓋壓觸 廠簾遞憲遞鬱夢鑰繭蓋 (積齋網壓憲齋遞餘艱襯 ) 更多 | 积极 | 2007-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用